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We investigated the molecular mechanism underlying curcumin depletion of ErbB2 protein. Curcumin induced ErbB2 ubiquitination but
pretreatment with proteasome inhibitors neither prevented curcumin depletion of ErbB2 protein nor further accumulated ubiquitinated ErbB2.
Curcumin increased association of endogenous and ectopically expressed CHIP, a chaperone-dependent ubiquitin ligase, with ErbB2. In COS7
cells cotransfected with ErbB2 and various CHIP plasmids followed by curcumin treatment, CHIP-H260Q (a mutant lacking ubiquitin ligase
activity) promoted less curcumin-induced ErbB2 ubiquitination than did wild type CHIP, and CHIP-K30A (a mutant incapable of binding Hsp90
and Hsp70) neither associated with ErbB2 nor promoted its ubiquitination. ErbB2 mutants lacking the kinase domain failed to associate with CHIP
and were completely resistant to ubiquitination and depletion induced by curcumin. Finally, curcumin's Michael reaction acceptor functionality
was required for both covalent association of curcumin with ErbB2 and curcumin-mediated ErbB2 depletion. These data suggest (1) that CHIP-
dependent ErbB2 ubiquitination is implicated in curcumin-stimulated ErbB2 depletion, and (2) that covalent modification of ErbB2 by curcumin
is the proximal signal which initiates this process.
© 2006 Elsevier B.V. All rights reserved.Keywords: Curcumin; ErbB2; Michael reaction; E3 ubiquitin ligase; Molecular chaperones1. Introduction
ErbB2 (HER2/neu) is a 185 kDa transmembrane tyrosine
kinase that acts as a coreceptor for the other epithelial growth
factor receptor (EGFR) family members, including EGF
receptor (ErbB1), ErbB3, and ErbB4. Although no ligand for
ErbB2 has been identified, ErbB2 heterodimerization with other
EGFR family members prolongs receptor signaling, activation
of multiple downstream pathways, and oncogenesis [1].
High expression of ErbB2 is frequently observed in many
types of human cancers including breast, ovarian, gastric, lung,
bladder, and kidney carcinomas. A growing body of evidence
from clinical as well as laboratory data has revealed that
overexpression of ErbB2 increases metastatic potential and
resistance to anti-cancer agents, and is associated with a poor
prognosis [2]. For this reason, therapeutic strategies that down-⁎ Corresponding author. Tel.: +82 51 510 2527; fax: +82 51 513 6754.
E-mail address: jungy@pusan.ac.kr (Y. Jung).
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doi:10.1016/j.bbamcr.2006.11.004regulate the level of ErbB2 protein and/or its activity, including
ErbB2 antibody [3], tyrosine kinase inhibitors [4], heat shock
protein (Hsp) 90 inhibitors such as geldanamycin (GA) [5], or
the polyphenolic natural product curcumin [6], have been
investigated as potential treatments for ErbB2-overexpressing
cancers.
Recently it was reported that the chaperone-dependent E3
ubiquitin ligase, carboxyl terminus of Hsc70-interacting protein
(CHIP), is involved in GA-induced ErbB2 degradation [7]. GA
fosters CHIP association with ErbB2 and subsequently induces
ubiquitination and degradation of the kinase via the proteasome.
These observations suggest that pharmacologic enhancement of
the CHIP–ErbB2 interaction may be therapeutically useful for
down-regulating ErbB2 activity.
Curcumin (1,7-bis (4-hydroxy-3-methoxyphenyl)-1,6-hepta-
diene-3,5-dione) is the major yellow pigment extracted from
turmeric derived from the rhizome of the plant Curcuma longa.
It is known to have numerous biological activities including
anti-inflammatory, antioxidant, and anti-proliferative properties
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prevention for its anti-proliferative and anti-carcinogenic
properties [9]. Recently, it was reported that curcumin down-
regulates cellular ErbB2 signaling in breast cancer cells by
depleting ErbB2 protein [6]. However, little is known regarding
the molecular mechanism underlying ErbB2 depletion by
curcumin. In this study, we show that curcumin-induced
ErbB2 depletion involves CHIP, requires the kinase domain
of ErbB2 and the Michael acceptor function of curcumin, but
surprisingly is independent of the proteasome.
2. Materials and methods
2.1. Cells, antibodies and plasmids
SKBr3 and COS7 cells were purchased from American Type Culture
Collection. Immunoprecipitating anti-ErbB2 antibodies (Ab-2, 5), which were
premixed before use, were from Oncogene Science Inc. (Cambridge, MA), and
Western blotting anti-ErbB2 antibodies (Ab-3 [clone 3B5] for the intracellular
domain and AB-3 [clone L87] for the extracellular domain) were from
Oncogene Science Inc. and NeoMarkers (Fremont, CA), respectively. Rabbit
anti-ubiquitin polyclonal antibody was from Sigma (St. Louis, MO). Rat anti-
Hsp90 monoclonal antibody (SPA-835) was from Stressgen Biotech Corp.
(Victoria, BC, Canada), and goat anti-Hsp/Hsc70 polyclonal antibody was from
Santa Cruz Biotechnology (Santa Cruz, CA). Plasmid constructs (wild type and
mutant ErbB2 plasmids and wild type and mutant CHIP plasmids) were
prepared as previously described [7,10]. Rabbit anti-CHIP polyclonal antibody
and purified CHIP protein were a kind gift of Dr. C. Patterson (University of
North Carolina, Chapel Hill, NC).
2.2. Drugs and chemicals
Curcumin (1,7-bis (4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-
dione) was purchased from LKT (St. Paul, MN). PS-341 and geldanamycin
were obtained from Millenium Pharmaceuticals (Cambridge, MA) and the
National Cancer Institute (Rockville, MD), respectively. ALLnL was purchased
from Sigma (St. Louis, MO). Radiolabeled curcumin ([3H], specific
activity=20 Ci/mmol) was purchased from Moravek Biochemicals Inc. (Brea,
CA). Tetrahydrocurcumin (THC) was prepared by Pd/C-reduction of curcumin
dissolved in ethanol in a pressure reactor (50 psi hydrogen). Formation of THC
was verified by NMR and IR.
2.3. Cell culture and transient transfection
SKBr3 cells were cultured in Dulbecco's modified Eagle's medium
(Biofluids, Rockville, MD), supplemented with 10% fetal bovine serum
(Invitrogen, Frederick, MD), 2 mM glutamine, 1 mM HEPES, and 100 units
of penicillin and streptomycin (Biofluids). COS7 cell culture medium contained
90% Dulbecco's modified Eagle's medium, 10% fetal bovine serum, 2 mM
glutamine, 1 mM HEPES and 1 mM sodium pyruvate. For transient
transfections, each plasmid was premixed with FuGene 6 (Roche Molecular
Biochemicals, South San Francisco, CA) and added to cells at 50–70%
confluency. Cells were continually cultured in the same medium for 24 h until
appropriate treatment.
2.4. Immunoprecipitation and western blotting
Cells were washed once with cold phosphate-buffered saline (pH 7.0) and
lysed by scraping in TMNSV buffer (50 mM Tris–HCl (pH 7.5), 20 mM
Na2MoO4, 0.09% Nonidet P-40, 150 mM NaCl, and 1 mM sodium
orthovanadate) supplemented with CompleteTM proteinase inhibitors (Roche
Molecular Biochemicals). Cell lysates were clarified by centrifugation at
14,000 rpm (4 °C) for 15 min, and protein concentration was determined by the
BCA method (Pierce). For immunoprecipitation, 0.5 mg–1 mg of lysates was
incubated with 2 μg of mouse monoclonal antibodies at 4 °C for 2 h, followed bythe addition of protein G-agarose beads (Invitrogen) and rotation at 4 °C
overnight. The beads were washed five times with TMNSV buffer, resuspended
in 1× SDS sample buffer (80 mM Tris–HCl (pH 6.8), 2% SDS, 10% glycerol,
100 mM dithiothreitol, and 0.0005% bromphenol blue), and boiled for 5 min.
Immunoprecipitated proteins or cell lysates mixed with 5× SDS sample buffer)
were separated by 4–20% gradient gel electrophoresis (BioRad). Western
blotting was performed as described previously [11].
2.5. Measurement of [3H]-curcumin bound to ErbB2
After a 1 h incubation of 3H-labeled curcumin with immunoprecipitated
ErbB2 in the presence or absence of appropriate chemicals, immunobeads were
washed thoroughly with buffer (50 mM Tris–HCl (pH 7.5), 1% Nonidet P-40,
150 mM NaCl), resuspended in 1× SDS sample buffer, and boiled for 5 min.
Immunoprecipitated ErbB2 was separated by 4–20% gradient gel electrophor-
esis and gels were stained with GelCode (Pierce, Rockford, IL) for 30 min–1 h.
Stained bands were excised and incubated for 24 h in NCS tissue solubilizer (GE
Healthcare, Piscataway, NJ) to extract ErbB2 protein. Eluates were mixed with
BSC-NA scintillation cocktail (GE Healthcare) and radioactivity was measured
using an LS 6500 liquid scintillation counting system (Beckman Coulter).
3. Results
3.1. Curcumin induces ErbB2 ubiquitination but not
proteasome-mediated degradation
Curcumin is reported to down-regulate ErbB2 protein [6]. To
investigate the molecular mechanism underlying curcumin-
induced ErbB2 depletion, we first examined whether curcumin
affected the stability of ErbB2 protein. ErbB2-overexpressing
SKBr3 cells were treated with cycloheximide, an inhibitor of
protein synthesis, in the presence or absence of curcumin, and
the level of ErbB2 protein was monitored at the indicated times.
As shown in Fig. 1A, in the absence of new protein synthesis
curcumin markedly reduced the level of pre-existing ErbB2
protein.
The Hsp90 inhibitor GA destabilizes ErbB2 protein via
ubiquitination and subsequent proteasomal degradation [11]. To
examine whether a similar process was involved in curcumin-
induced destabilization of ErbB2, we treated SKBr3 cells with
curcumin in the presence or absence of the proteasome inhibitor
PS-341. For comparison, cells were treated with GA. ErbB2
protein was immunoprecipitated and its ubiquitination status
was examined by Western blotting. Consistent with a previous
report [11], GA rapidly induced proteasome inhibitor-enhanced
ErbB2 ubiquitination (Fig. 1B), and its proteasome-mediated
degradation (Fig. 1C). Interestingly, although curcumin also
induced ErbB2 ubiquitination, its onset was slower than that
caused by GA and was not further enhanced by concomitant
proteasome inhibition (Fig. 1B), nor could curcumin-induced
depletion of ErbB2 be rescued by proteasome inhibition (Fig.
1C). Lysosomal inhibitors failed to protect ErbB2 from
curcumin-induced degradation (data not shown).
3.2. CHIP participates in curcumin-induced ErbB2
ubiquitination
CHIP plays a role in both GA-enhanced and steady-state
ubiquitination of ErbB2 [7,12]. We wondered whether CHIP
served as a ubiquitin ligase in the case of curcumin-induced
Fig. 1. Curcumin induces ubiquitination and degradation of ErbB2 in SKBr3
cells. (A) SKBr3 cells were either left untreated or were treated with curcumin
(50 μM) for 1 h, followed by addition of cycloheximide (100 μM) for the
indicated times. Cellular levels of ErbB2 protein were visualized from whole cell
lysates (20 μg). The blot was reprobed for tubulin as a control for equal loading.
(B) SKBr3 cells, either left untreated or treated with curcumin (50 μM) or GA
(1 μM) for the indicated times in the presence or absence of the proteasome
inhibitor PS-341 (1 μM), were lysed in TMNSV buffer. ErbB2 proteins were
immunoprecipitated as described in Materials and methods, solubilized in SDS
sample buffer, and separated by SDS-PAGE. Blots were probed with anti-ErbB2
or anti-ubiquitin antibodies. (C) SKBr3 cells were treatedwith curcumin or GA in
the presence or absence of either PS-341 or ALLnL (100 μM) for 4 h. Cellular
levels of ErbB2 protein were visualized as above. In the experiments shown in
(B) and (C) cells were pre-treated with PS-341 for 30 min, and the inhibitor was
then present continuously for the remainder of the experiment.
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curcumin induced endogenous CHIP/ErbB2 association in
SKBr3 cells. Cells were treated with curcumin for 1.5 h,
ErbB2 protein was immunoprecipitated, and coimmunopreci-
pitated CHIP was examined by Western blotting. As shown in
Fig. 2A, CHIP was barely detectable in the ErbB2 immuno-
complex isolated from untreated cells, but curcumin treatment
markedly increased CHIP coimmunoprecipitation. We next
examined whether curcumin could enhance association of CHIP
with ErbB2 protein in vitro. After immunoprecipitating ErbB2
from SKBr3 lysate, we treated the immunopellets with
curcumin, and then washed and incubated the immunopellets
in lysis buffer containing purified CHIP protein. After washing,
we detected CHIP and ErbB2 in the immunopellets by Western
blotting. As shown in Fig. 2B, CHIP level in the curcumin-
treated immunopellet was markedly increased.
Since curcumin enhanced association of CHIP with ErbB2,
we determined whether CHIP could act as a ubiquitin ligase
mediating curcumin-induced ErbB2 ubiquitination. To do this,we compared the level of curcumin-induced ubiquitination of
ErbB2 in the presence of wild type (CHIP-WT) or E3 ligase-
deficient (CHIP-H260Q) CHIP protein. COS7 cells were
transfected with ErbB2 and either CHIP-WT or CHIP-H260Q,
and 24 h later the transfected cells were treated with curcumin
for an additional 1.5 h. ErbB2 proteins were immunoprecipi-
tated, and CHIP and ubiquitinated ErbB2 in the immunopellets
were examined by Western blotting. As shown in Fig. 2C,
curcumin induced both CHIP-WT association with and
ubiquitination of ErbB2. That the curcumin-induced ErbB2
ubiquitination was CHIP-dependent is suggested by the finding
that curcumin-induced ErbB2 ubiquitination was significantly
reduced in COS7 cells transfected with ErbB2/CHIP-H260Q
although, as previously reported [7,12], association of this
inactive CHIP mutant with ErbB2 was much greater than that
seen with CHIP-WT. If CHIP-dependent ErbB2 ubiquitination
is related to curcumin-induced ErbB2 depletion, expression of
CHIP-H260Q should at least partially protect ErbB2 from the
effects of curcumin treatment. This is indeed what we observed
(see Fig. 2D). When COS7 cells were transfected with CHIP-
WT, ErbB2 depletion following curcumin (4 h exposure) was
more pronounced than in cells not transfected with CHIP.
Indeed, in the presence of over-expressed CHIP-WT protein,
ErbB2 steady-state expression was reduced even in the absence
of curcumin. However, in COS7 cells expressing ubiquitin
ligase-deficient CHIP-H260Q protein, ErbB2 was partially
protected from the effects of curcumin.
3.3. Involvement of molecular chaperones in curcumin-induced
ErbB2 ubiquitination
Since CHIP is thought to depend on the molecular chaperones
Hsp70 and/or Hsp90 to bring it into contact with its substrates
[13], we examinedwhether a chaperone complex was required for
CHIP-mediated ErbB2 ubiquitination induced by curcumin.
ErbB2 and CHIP-WT or CHIP-K30A (a mutant incapable of
binding to both Hsp90 and Hsp70) were transfected into COS7
cells and 24 h later the cells were treated with curcumin for an
additional 1.5 h. ErbB2 proteins were immunoprecipitated and
CHIP and ubiquitinated ErbB2 were examined by Western
blotting. Consistent with our earlier data, curcumin enhanced
CHIP-WT binding to and ubiquitination of ErbB2 (Fig. 3A; also
see Fig. 2C). In contrast, co-transfection of CHIP-K30A
prevented curcumin-induced ErbB2 ubiquitination (Fig. 3A).
However, unlike the enzymatically inactive CHIP-H260Q, CHIP-
K30A failed to associate with ErbB2, indicating that binding to a
chaperone intermediate may be required for CHIP-dependent
ErbB2 ubiquitination induced by curcumin. Alternatively, the
data in Fig. 2B suggest that CHIP may interact directly with
curcumin-modified ErbB2 (see also Fig. 5). Thus, we cannot rule
out the possibility that the TPR domain mutation of CHIP-K30A,
which prevents its interaction with Hsp90 and Hsp70, may also
abrogate its ability to interact directly with ErbB2.
GA treatment remodels the ErbB2–chaperone complex,
reducing association of Hsp90 while increasing the association
of Hsp/Hsc70 [7]. We wondered whether a similar remodeling
of the ErbB2–chaperone complex occurred following curcu-
Fig. 2. CHIP participates in curcumin-induced ubiquitination of ErbB2. (A) SKBr3 cells, either left untreated or treated with curcumin for 1.5 h, were lysed in TMNSV
buffer. ErbB2 protein in 0.5 mg cell lysate was immunoprecipitated (IP) using as described under Materials and methods. Immunoprecipitated proteins were
solubilized in SDS sample buffer and separated by 4–20% SDS-PAGE. Blots were probed with anti-ErbB2 (for immunoprecipitation efficiency) or anti-CHIP
antibodies. IB, immunoblot. (B) SKBr3 cells were lysed in TMNSV buffer. ErbB2 proteins were immunoprecipitated and the immunopellets were treated (d) or left
untreated (c) with curcumin (50 μM) for 1 h, and then were washed and incubated in lysis buffer containing purified CHIP protein (100 ng/ml) for 1 h. The
immunopellets were solubilized in SDS sample buffer and separated by 4–20% SDS-PAGE. Blots were probed with appropriate antibodies. Lanes a (beads+ErbB2
antibodies+CHIP) and b (beads+cell lysate+CHIP) represent controls. (C) COS7 cells were transfected with ErbB2 together with either wild type CHIP (CHIP-WT)
or CHIP-H260Q (a U box mutant lacking ubiquitin ligase activity). After 24 h, cells were treated with or without curcumin for 1.5 h. ErbB2 proteins were
immunoprecipitated (IP), solubilized in SDS sample buffer and separated by SDS-PAGE. Blots were probed with appropriate antibodies. (D) COS7 cells were
transiently transfected with either ErbB2 alone or together with CHIP-WTor ubiquitin ligase-deficient CHIP-H260Q. The following day, cells were treated or not with
curcumin for 4 h. ErbB2 levels were monitored by Western blot. Tubulin is shown as a loading control.
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ErbB2 protein was immunoprecipitated. Coimmunoprecipita-
tion of Hsp90 and Hsp/Hsc70 was examined by Western
blotting. As shown in Fig. 3B, unlike GA curcumin recruited
both Hsp90 and Hsp/Hsc70 to an ErbB2 immunocomplex. We
suspected that Hsp90 could be recruited to curcumin-modified
ErbB2 in a manner distinct from its normal association with the
kinase. To investigate this possibility, we utilized ErbB2-5M in
which the Hsp90 binding loop of ErbB2 has been replaced with
the same loop in EGFR (to which Hsp90 does not bind) [10].
ErbB2-5M in addition to not binding Hsp90 is quite resistant to
the effects of GA [10,14]. COS7 cells were cotransfected with
CHIP-WT and either ErbB2-WT or ErbB2-5M, as previously
described, and the cells were treated with curcumin for 1.5 h.
ErbB2 proteins were immunoprecipitated and co-immunopre-
cipitated Hsp90, Hsp/Hsc70, and CHIP were examined by
Western blotting. As shown in Fig. 3C, curcumin recruited a
large amount of Hsp90 to ErbB2-WT but not to ErbB2-5M.
These data demonstrate that Hsp90 associated with ErbB2 in the
presence of curcumin bound to the same region of the kinase as
does Hsp90 under steady-state conditions. In contrast, the
amount of Hsp/Hsc70 recruited to ErbB2 by curcumin was
modest but was not affected by ErbB2 mutation.Since ErbB2-WT coprecipitated with CHIP to a greater
extent than did ErbB2-5M upon curcumin treatment, and
because curcumin induced a greater ubiquitination of ErbB2-
WT compared to ErbB2-5M, we examined whether Hsp90
recruitment was necessary for curcumin-induced ErbB2 deple-
tion. To do this, we compared the curcumin sensitivity of
ErbB2-WT and ErbB2-5M in the presence of CHIP-WT. As
shown in Fig. 3D, ErbB2-5M was depleted somewhat more
slowly than was ErbB2-WT upon curcumin treatment, suggest-
ing that although Hsp90 might provide a positive contribution
to CHIP-dependent ErbB2 depletion, its presence is not
absolutely necessary. Whether the small amount of Hsp/
Hsc70 recruited by curcumin to ErbB2-5M mediates ErbB2
depletion in the absence of Hsp90, or whether modification of
ErbB2 by curcumin (see below) recruits CHIP directly to the
kinase remains to be conclusively determined.
3.4. ErbB2 kinase domain is required for curcumin-induced,
CHIP-dependent ubiquitination and degradation
The ErbB2 kinase domain is required for GA-induced and
CHIP-dependent ErbB2 ubiquitination and degradation [7]. We
examined whether curcumin required a similar motif to induce
Fig. 3. Curcumin recruited-Hsp90 positively regulates CHIP-dependent ErbB2 ubiquitination. (A) SKBr3 cells, either left untreated or treated with curcumin for 1.5 h,
were lysed in TMNSV buffer. ErbB2 protein in 0.5 mg cell lysate was immunoprecipitated (IP), solubilized in SDS sample buffer, and separated by 4–20% SDS-
PAGE. Blots were probed with anti-ErbB2 (for immunoprecipitation efficiency), anti-Hsp90 or anti-Hsp/Hsc70 antibody. IB, immunoblot. (B) COS7 cells were
transfected with ErbB2 together with either CHIP-WT or CHIP-K30A (a CHIP mutant incapable binding to Hsp90 or Hsp70). After 24 h, cells were treated with or
without curcumin for 1.5 h. 1 mg of cell lysate was immunoprecipitated (IP) using anti-ErbB2 antibodies, solubilized in SDS sample buffer, and separated by SDS-
PAGE. Blots were probed with anti-ErbB2, anti-ubiquitin or anti-CHIP antibody. (C) COS7 cells were transfected with ErbB2 (WT) or ErbB2-5M (5 M, an ErbB2
mutant incapable of binding to Hsp90) together with CHIP for 24 h, followed by treatment with or without curcumin for 1.5 h. Immunoprecipitation and
immunoblotting were performed as in “B”. Blots were probed with anti-ErbB2 (for immunoprecipitation efficiency), anti-CHIP, anti-ubiquitin, anti-Hsp90 or anti-Hsp/
Hsc70 antibody. (D) COS7 cells were cotransfected with CHIP and either ErbB2 (WT) or ErbB2-5M (5 M) for 24 h, followed by treatment with or without curcumin
for the indicated times. Cell lysates (40 μg) were mixed with 5× SDS sample buffer and separated by 4–20% SDS-PAGE. Blots were probed with anti-ErbB2 antibody.
Percent remaining was determined by densitometric analysis of the blots.
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fected with CHIP-WT and various ErbB2 truncation constructs
as shown in Fig. 4A. After 24 h, cells were treated with
curcumin for 3 h and ErbB2 proteins were immunoprecipitated
as described above. Ubiquitinated ErbB2 and CHIP in the
immunocomplex were examined by Western blotting. As
shown in Fig. 4B, curcumin induced CHIP association with
and ubiquitination of only full-length ErbB2 and ErbB2-DHC
(deletion of 224 amino acids C-terminal to the kinase domain),
but not of ErbB2/Δ750–971 (an ErbB2 construct with an
internal deletion of the kinase domain) or ErbB2/DK (deletion
of most of the intracellular domain). We next examined whether
curcumin-induced ErbB2 ubiquitination via CHIP association
correlated with curcumin sensitivity of the different ErbB2
constructs. COS7 cells were cotransfected with CHIP-WT and
the various ErbB2 constructs as described and were treated with
curcumin for 5 h. ErbB2 protein was monitored by Western
blotting. As shown in Fig. 4C, while full-length ErbB2 and
ErbB2-DHC (including the kinase domain) were depleted by
curcumin, ErbB2-DK and ErbB2/Δ750–971 proteins (not
including the kinase domain) were resistant.3.5. The Michael reaction acceptor functionality of curcumin is
required for ErbB2 depletion
Since we had reason to believe that curcumin may directly
modify ErbB2, we explored whether curcumin's Michael
reaction acceptor functionality was necessary. Curcumin
contains two Michael reaction (nucleophile) acceptors. We
reduced curcumin using Pd/C under 50 psi hydrogen to
obtain tetrahydrocurcumin, which lacks Michael reaction
acceptor activity, and we compared the ability of tetrahy-
drocurcumin with that of curcumin to deplete ErBb2 in
SKBr3 cells. For comparison, the structures of curcumin and
tetrahydrocurcumin are shown in Fig. 5A. Tetrahydrocurcu-
min did not deplete ErbB2 at concentrations up to 100 μM,
indicating that a Michael reaction acceptor in curcumin is
required for its ability to promote ErbB2 depletion. We
wondered whether the effect of this chemical functionality on
ErbB2 depletion was general. To examine this question, we
treated SKBr3 cells with several structurally distinct
compounds which have Michael reaction acceptor function-
ality (Fig. 5B) and we monitored their effect on ErbB2 level.
Fig. 4. ErbB2 kinase domain is required for curcumin-induced CHIP-dependent ubiquitination of ErbB2. (A) Schematic description of ErbB2 constructs used in the
experiments. (B) COS7 cells in 10 cm dishes were transfected with CHIP, plus full-length, truncated or internal-deleted ErbB2 constructs. Twenty-four hours after
transfection, cells, either left untreated or treated with curcumin for 3 h, were lysed with TMNSV buffer. For immunoprecipitation (IP), 1 mg of cell lysate was
incubated with anti-ErbB2 antibodies, and the immunocomplex was precipitated with protein-G-agarose beads. Immunoprecipitated proteins were solubilized in SDS
sample buffer and separated by SDS-PAGE. Blots were probed with anti-ErbB2 (AB-3, Neomarkers), anti-ubiquitin or anti-CHIP antibody. (C) Cell lysates (40 μg)
obtained from the transfected COS7 cells treated with or without curcumin for 5 h were mixed with 5× SDS sample buffer and separated by 4–20% SDS-PAGE. Blots
were probed with anti-ErbB2 antibody (AB-3, Neomarkers).
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(Fig. 5B).
Since covalent modification of a protein involves reaction
between nucleophile(s) on the protein and nucleophile accep-
tors [15], we speculated that curcumin may exert its effects on
ErbB2, at least in part, by covalent association with the kinase.
To test this hypothesis, we incubated [3H] curcumin with ErbB2
that had been immunoprecipitated from SKBr3 cells. After 1 h
incubation with labeled curcumin, the immunoprecipitated
ErbB2 was separated by SDS-PAGE and the gel was stained.
Bands corresponding to ErbB2 were excised and extracted for
24 h followed by measurement of radioactivity, as described in
Methods. A control gel slice was prepared by cutting out an
amount of gel matching the ErbB2 band (at approximately the
same location) obtained after electrophoresis of a sample
prepared from incubating [3H] curcumin with beads obtained
from the immunoprecipitation process without anti-ErbB2
antibodies. To test whether Michael reaction acceptor function-
ality was required for covalent association, we performed the
same experiment after pre-treating the immunoprecipitated
ErbB2 with either excess non-radioactive curcumin (50 μM) or
tetrahydrocurcumin (100 μM). As shown in Fig. 5C, while
incubation of ErbB2 with labeled curcumin increased ErbB2-
associated radioactivity more than 3-fold, pretreatment with
unlabeled curcumin, but not with tetrahydrocurcumin, markedly
reduced the ErbB2-associated radioactivity. These data indicate
that curcumin covalently binds to ErbB2 through a Michael
reaction acceptor functionality.Finally, we wished to explore the relevance of covalent
association of curcumin with ErbB2 to curcumin's ability to
deplete ErbB2. Since the kinase domain of ErbB2 was required
for curcumin depletion, we examined whether curcumin bound
to the kinase domain. [3H] curcumin was incubated with either
ErbB2-WT or ErbB2/Δ750–971 immunoprecipitated from
COS7 cells. The radioactivity associated with ErbB2 was
determined as described above. As shown in Fig. 5D, while
incubation of ErbB2 with labeled curcumin resulted in an
approximately 2-fold increase in signal compared to control,
incubation of ErbB2/Δ750–971 with labeled curcumin did not
produce a radioactive signal above background, supporting the
hypothesis that the kinase domain of ErbB2 contains the
binding site for curcumin. In contrast, using [3H] 17AAG we
could detect no covalent association with either WT or mutant
ErbB2 proteins (data not shown).
4. Discussion
Our data demonstrate that CHIP mediates curcumin-induced
ubiquitination of ErbB2 and that the kinase domain of ErbB2 is
required for curcumin-induced ErbB2 ubiquitination and
degradation. Moreover, curcumin's Michael reaction acceptor
functionality appears to be the pharmacophore responsible for
curcumin's ability to promote ErbB2 degradation.
Although curcumin induced ErbB2 ubiquitination, we found
that ubiquitinated ErbB2 did not further increase in the presence
of proteasome inhibitors. Furthermore, consistent with a
Fig. 5. The Michael reaction acceptor functionality of curcumin is required for curcumin-mediated ErbB2 depletion. (A) Upper panel, chemical structures of
tetrahydrocurcumin (THC) and curcumin; the functional group in the boxes indicates Michael reaction acceptor. Lower panel, SKBr3 cells were treated with THC (50,
100 μM) or curcumin (50 μM) for 4 h and lysed to obtain whole cell lysates. Western blotting was performed to monitor ErbB2 levels. The membrane was reprobed
with tubulin to verify equivalent loading. (B) Upper panel, chemical structures of ρ12-PGJ2 (PG), Dibenzylideneacetone (D), and Parthenolide (P); the functional
group in the boxes indicates Michael reaction acceptor. Lower panel, SKBr3 cells were treated with curcumin (C, 50 μM), PG (50 μM), D (20 μM) or P (20 μM) for 4 h
and lysed to obtain whole cell lysates. Western blotting was performed to monitor ErbB2 levels. The membrane was reprobed with tubulin to verify equivalent loading.
(C) After a 1-h incubation of 3H-labeled curcumin with ErbB2 immunoprecipitated from SKBr3 cells, immunobeads were washed thoroughly with buffer (50 mM
Tris–HCl, pH 7.5, 1% Nonidet P-40, 150 mMNaCl), resuspended in 1× SDS sample buffer and boiled for 5 min. Immunoprecipitated ErbB2 was separated by 4–20%
SDS-PAGE and the gel was stained for 30 min. The stained band was cut out and incubated (24 h) in NCS tissue solubilizer to extract ErbB2 protein. The eluates were
mixed with BSC-NA scintillation cocktail and radioactivity in the eluates was measured using a liquid scintillation counter. *: control (see text). The same experiment
was done after 1 h pretreatment with excess unlabeled THC or curcumin. (D) The same experiment as in C was performed using either WT ErbB2 or kinase domain-
deleted ErbB2 (Δ750–971) that had been immunoprecipitated from COS7 cells. Ctrl: control (prepared as in C).
389Y. Jung et al. / Biochimica et Biophysica Acta 1773 (2007) 383–390previous report [16], proteasome inhibitors did not prevent
curcumin-induced ErbB2 depletion. These data suggest that
ubiquitinated ErbB2 accumulating in response to curcumin is
not degraded via a proteasomal pathway. A recent report
demonstrating that curcumin inhibits proteasomal activity by up
to 90% [17] supplies a possible explanation for this phenom-
enon. The proteolytic pathway mediating curcumin-induced
ErbB2 depletion remains under investigation. Recognition of
ubiquitinated substrates by non-proteasomal proteolytic path-
ways has been described [18–20]. Lysosomal inhibitors failed
to protect ErbB2 from curcumin-induced degradation (data not
shown).
Participation of the ubiquitin ligase CHIP in curcumin-
induced ErbB2 ubiquitination is supported by our data showing
that (1) curcumin enhanced endogenous CHIP association with
ErbB2 in SKBr3 cells, and in COS-7 cells transiently co-
transfected with ErbB2 and CHIP plasmids; (2) curcumin
increased association of CHIP with immunoprecipitated ErbB2
in vitro; (3) curcumin induced less ErbB2 ubiquitination inCOS7 cells transiently transfected with ubiquitin ligase-
deficient CHIP-H260Q; (4) transfection with CHIP-H260Q
partially protected ErbB2 from curcumin-induced depletion; (5)
CHIP-K30A, a mutant incapable of binding to both Hsp90 and
Hsp70, did not support curcumin-induced ErbB2 ubiquitination.
In contrast to an earlier observation that the Hsp90 inhibitor
GA promotes CHIP-dependent ErbB2 ubiquitination concomi-
tant with Hsp90 dissociation from the kinase [7], our data
demonstrate that curcumin-induced CHIP association with
ErbB2 and subsequent ErbB2 ubiquitination occur together
with enhanced recruitment of Hsp90 to ErbB2. Thus, curcumin-
induced CHIP association with and subsequent ubiquitination
of ErbB2 were markedly reduced in COS7 cells transiently
transfected with CHIP-WT and ErbB2-5M, an ErbB2 mutant
that does not bind Hsp90 [10]. Nonetheless, in agreement with
an earlier report [14], ErbB2-5M remains sensitive to curcumin,
suggesting that Hsp90 recruitment to ErbB2 may enhance but is
not essential for curcumin-induced degradation. However, our
data demonstrate that truncated or internally deleted ErbB2
390 Y. Jung et al. / Biochimica et Biophysica Acta 1773 (2007) 383–390mutants lacking a kinase domain fail to associate with CHIP and
are neither ubiquitinated nor degraded in response to curcumin.
Lastly, our results demonstrate that the Michael reaction
acceptor functionality of curcumin is required both for ErbB2
depletion and for covalent association of curcumin with ErbB2.
This is in contrast to the Hsp90 inhibitor 17AAG, for which no
evidence exists of direct modification of ErbB2. We found that
the ErbB2 kinase domain, required for ErbB2 sensitivity to
curcumin, is a potential site for covalent association of
curcumin. Since thiols are more nucleophilic than amines in
an aqueous biological environment, we think it most likely that
thiols (especially ones surrounded by acidic or basic amino
acids) are the predominant targets of curcumin-mediated
covalent modification. This prediction is currently being tested.
Since structurally different compounds with the same Michael
reaction acceptor functionality were also able to deplete ErbB2,
our data suggest that one might be able to design an effective
ErbB2 targeting drug by chemical modification(s) of a lead
compound to modulate its Michael reaction acceptor activity
and affinity for ErbB2. Considering its relative safety, curcumin
could be used as such a lead compound.
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